Thomas A. Raffin - 25 Aug 2022 Form 4 Insider Report for LUMOS PHARMA, INC.

Role: Director
Signature: /s/ Ryan Trytten, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 25 Aug 2022
Net transactions value: +$9,729
Form type: 4
Filing time: 26 Aug 2022, 17:00:21 UTC
Previous filing: 03 Jun 2022
Next filing: 12 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LUMO	Common Stock	Purchase	$9,729	+1,150	+14%	$8.46	9,406	25 Aug 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 237 restricted stock units ("RSUs") previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in a single installment on April 3, 2023, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.

Content

Includes 237 restricted stock units ("RSUs") previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in a single installment on April 3, 2023, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.